These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35576521)

  • 1. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
    Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
    J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based simulation to support the extended dosing regimens of atezolizumab.
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
    Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
    J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.
    Bi Y; Liu J; Furmanski B; Zhao H; Yu J; Osgood C; Ward A; Keegan P; Booth BP; Rahman A; Wang Y
    Ann Oncol; 2019 Apr; 30(4):644-651. PubMed ID: 30715147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
    Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
    J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
    Kicken MP; Deenen MJ; Moes DJAR; Hendrikx JJMA; van den Borne BEEM; Dumoulin DW; van der Wekken AJ; van den Heuvel MM; Ter Heine R
    Target Oncol; 2024 Sep; 19(5):779-787. PubMed ID: 39085452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
    Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
    J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
    Geoerger B; Zwaan CM; Marshall LV; Michon J; Bourdeaut F; Casanova M; Corradini N; Rossato G; Farid-Kapadia M; Shemesh CS; Hutchinson KE; Donaldson F; Liao M; Caron H; Trippett T
    Lancet Oncol; 2020 Jan; 21(1):134-144. PubMed ID: 31780255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
    Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
    Wu B; Sternheim N; Agarwal P; Suchomel J; Vadhavkar S; Bruno R; Ballinger M; Bernaards CA; Chan P; Ruppel J; Jin J; Girish S; Joshi A; Quarmby V
    Clin Transl Sci; 2022 Jan; 15(1):130-140. PubMed ID: 34432389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Felip E; Burotto M; Zvirbule Z; Herraez-Baranda LA; Chanu P; Kshirsagar S; Maiya V; Chan P; Pozzi E; Marchand M; Monchalin M; Tanaka K; Tosti N; Wang B; Restuccia E
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1142-1155. PubMed ID: 33788415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
    Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
    Yu T; Liu X; Wu CY; Tang Z; Wang H; Schnell P; Wan Y; Wang K; Liu L; Gao Y; Sahasranaman S; Budha N
    Clin Transl Sci; 2024 Mar; 17(3):e13769. PubMed ID: 38515348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
    Zhao X; Suryawanshi S; Hruska M; Feng Y; Wang X; Shen J; Vezina HE; McHenry MB; Waxman IM; Achanta A; Bello A; Roy A; Agrawal S
    Ann Oncol; 2017 Aug; 28(8):2002-2008. PubMed ID: 28520840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.